The Foundation for Radiopharmaceutical Innovation: Theragenics' Infrastructure & Isotope Production

A leading manufacturer of Pd-103, we produce multiple kilocuries a year to meet global demand for brachytherapy seeds. With a half-life of 17 days, Pd-103 can be centrally produced and distributed worldwide. While best known for its brachytherapy applications delivering localized radiation, its unique decay characteristics also present potential for other therapeutic applications.

We are positioned to produce commercial quantities of Cu-64 leveraging our specialized targety and cyclotrons. Utilized for PET imaging, its decay properties make it a valuable tool for visualizing various biological processes and disease states. With a half-life of 12.7 hours, our central production facility allows for efficient and broad distribution of the isotope.

We possess a Drug Master File (DMF) for Ga-67 and have proven processes for producing commercial quantities of this radioisotope using our high-capacity cyclotrons. Its 3.3-day half-life supports central production and broad distribution for SPECT imaging. Ga-67 is valuable in detecting and staging inflammatory and infectious diseases, as well as certain cancers.

With a 2.8 day half-life facilitating central production and distribution, we have proven processes for producing commercial quantities of In-111 using our high-capacity cyclotrons. This radioisotope is primarily used in SPECT imaging for a variety of diagnostic applications, including the detection of tumors, infections, and inflammatory processes.

We have extensive experience handling and distributing I-125, producing and shipping tens of thousands of brachytherapy seeds annually for global use. With a half-life of 59.4 days, I-125 is ideal for low-dose-rate (LDR) brachytherapy in the treatment of prostate cancer and other localized tumors. Our proven logistics and manufacturing infrastructure support high-volume, international distribution with exceptional reliability.

We have hands-on experience handling Sn-117m for medical devices. With a 14-day half-life, Sn-117m is well-suited for global distribution and sustained therapeutic use. This low-energy emitter is primarily used for the treatment of painful bone metastases and certain veterinary orthopedic conditions.

We have deep experience with Y-90, having developed a radioembolization product widely used in the treatment of liver cancer. With a 2.7-day half-life, Y-90 supports centralized production and broad distribution for therapeutic applications. This high-energy beta emitter is ideal for targeted internal radiation therapy, delivering localized treatment to tumors while minimizing exposure to surrounding healthy tissue.

With a half-life of 3.3 days, supporting central production and broad distribution, we have the capability to produce commercial quantities of Zr-89 utilizing our high-capacity cyclotrons. This positron-emitting radioisotope is increasingly used in PET imaging, particularly for antibody-based imaging and tracking cell migration in oncology and immunology. Our infrastructure is equipped to meet the growing demand for this important PET tracer.

This beta-emitting radioisotope, with a half-life of 3.8 days, holds significant potential for therapeutic applications, including the treatment of bone pain from metastatic cancer and radioembolization of liver tumors. We are well positioned to supply commercial quantities of this promising therapeutic isotope as demand grows.  

While production of Ac-225 presents unique challenges, our cyclotron infrastructure and expertise position Theragenics to be a key commercial manufacturer of this emerging therapeutic isotope as clinical applications expand. Ac-225 is an alpha-emitting radioisotope with a 10-day half-life showing significant promise in targeted radionuclide therapy for various cancers.

With deep expertise in Pd-103 production, we are uniquely positioned to access and handle Rh-103m, which decays from Pd-103. Its potent Auger electron emissions make it a promising candidate for targeted internal radiotherapy. Our production infrastructure and isotope handling capabilities support future therapeutic applications of this emerging radioisotope.